红细胞生成素对大鼠阿霉素性心肌病的预防

Objective To investigate the preventive effect and potential mechanisms of erythropoietin (EPO) against doxorubicin (DOX)-induced cardiomyopathy. Methods Thirty-one Wistar rats were randomly divided into DOX group (n=12) , DOX + EPO group (n=11) and control group (n=8). Dilated cardiomyopathy was induced by intraperitoneal injection of DOX for both DOX group and DOX+EPO group, and normal saline or EPO was administered before DOX injection for preventive purpose. Left ventricular systolic function was evaluated by invasive haemodynamic measurements among three groups. Rats were then sacrificed for Masson-stained histopathology observation and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) analysis of apoptosis, with immunological detection for Bax and Bcl-2 by Western blotting. Results There was significant difference in left ventricular systolic function between DOX group and DOX+EPO group. The area ratio of myocardial fibrosis was significantly decreased from (12.14±1.07)% in the DOX group to (7.49±1.11)% in the DOX+EPO group (P<0.05). The apoptotic index was (0.93±0.08)% and (0.16±0.04)% in the DOX group and DOX + EPO group (P<0.05) , respectively. Western blotting showed that Bcl-2 protein expression was decreased in DOX group compared to control group, but significantly increased in the DOX + EPO group compared to DOX group (P<0.05). Conclusions EPO can protect against DOX-induced cardiomyopathy via anti-apoptotic pathways. The up-regulation of Bcl-2 protein expression may contribute to the protection.

Prevention with erythropoietin against doxorubicin-induced cardiomyopathy in rats